Login
$JAZZ
$239.77 -$1.78 (0.74%) Live

$JAZZ SEC Filings

Filed On Filing
10 Nov 2026 Form 4: Cozadd Bruce C, Director

Received 86,500 shares by exercise or conversion ($11.8M) · Sold 68,808 shares ($16.2M)

06 Nov 2026 Form 4: Carr Patricia, SVP, Chief Accounting Officer

Received 1,250 shares by exercise or conversion ($175K) · Sold 1,413 shares ($327K)

06 Nov 2026 144
05 Nov 2026 Form 4: Gala Renee D, Director

Sold 1,000 shares ($225K)

05 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 Form 4: Cozadd Bruce C, Director

Sold 6,000 shares ($1.3M)

04 Nov 2026 144
03 Nov 2026 144
02 Nov 2026 144
02 Nov 2026 10-Q
02 Nov 2026 8-K: Results of Operations and Financial Condition

– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) –

26 Oct 2026 8-K: Results of Operations and Financial Condition

Estimated Q3 Financial Impacts Related to the Actio Biosciences, Inc. Acquisition

09 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company”), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier ...

08 Oct 2026 144
07 Oct 2026 Form 4: Gala Renee D, Director

Sold 2,000 shares ($473K)

06 Oct 2026 144
05 Oct 2026 Form 4: Cozadd Bruce C, Director

Sold 6,000 shares ($1.38M)

01 Oct 2026 144
23 Sep 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

This AMENDMENT No. 4, dated as of September 23, 2026 (this “Amendment”), to the Credit Agreement, dated as of May 5, 2021 (as amended by that certain LIBOR Successor Rate Conforming Changes Amendment, dated as of June 7, 2023, that certa...

15 Sep 2026 8-K: Regulation FD Disclosure

Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support